Methods and apparatus to treat and prevent atrial tachyarrhythmias
First Claim
1. A cardiac rhythm management system, comprising:
- an implantable tachyarrhythmia detection and classification circuit programmed to detect and classify a tachyarrhythmia;
an implantable biologic therapy delivery device comprising an agent delivery device and a gene regulatory signal delivery device, the agent delivery device configured to deliver one or more agents including an expression cassette suitable for transiently terminating or preventing AF, the gene regulatory signal delivery device configured to deliver a regulatory signal carrying a form of energy suitable for regulating the expression cassette;
a composition comprising the expression cassette comprising an energy regulatable transcriptional control element operably linked to a nucleic acid sequence for a gene product, wherein the gene product comprises sequences corresponding to those for an ion channel protein, a connexin, or a fragment thereof, wherein expression from the expression cassette in the atria of the mammal downregulates IKur, IK1 or If or upregulates connexin expression or activity; and
an implant control circuit coupled to the tachyarrhythmia detection and classification circuit and the biologic therapy delivery device, the control circuit programmed to trigger the delivery of the one or more agents including the expression cassette and the regulatory signal from the biologic therapy delivery device in an amount effective to restore or prolong action potential duration(APD) and/or effective refractory period (ERP) in response to a detection of a tachyarrhythmia classified as AF.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides a cardiac rhythm management system which includes a tachyarrhythmia detection and classification circuit programmed to detect and classify a tachyarrhythmia, a biologic therapy delivery device configured to deliver or regulate an expression cassette suitable for terminating or preventing atrial fibrillation (AF), and a control circuit coupled to the tachyarrhythmia detection and classification circuit and the biologic therapy delivery device. Also provided is an implantable medical device for use in a body having a cardiovascular system, which includes an implantable device body including at least a cardiovascular portion configured to be in the cardiovascular system, and an expression cassette incorporated into the cardiovascular portion of the implantable device body, the expression cassette selected to express a gene product that terminates or prevents AF. Further provided are methods which employ particular expression cassettes to prevent, inhibit or treat AF.
-
Citations
21 Claims
-
1. A cardiac rhythm management system, comprising:
-
an implantable tachyarrhythmia detection and classification circuit programmed to detect and classify a tachyarrhythmia; an implantable biologic therapy delivery device comprising an agent delivery device and a gene regulatory signal delivery device, the agent delivery device configured to deliver one or more agents including an expression cassette suitable for transiently terminating or preventing AF, the gene regulatory signal delivery device configured to deliver a regulatory signal carrying a form of energy suitable for regulating the expression cassette; a composition comprising the expression cassette comprising an energy regulatable transcriptional control element operably linked to a nucleic acid sequence for a gene product, wherein the gene product comprises sequences corresponding to those for an ion channel protein, a connexin, or a fragment thereof, wherein expression from the expression cassette in the atria of the mammal downregulates IKur, IK1 or If or upregulates connexin expression or activity; and an implant control circuit coupled to the tachyarrhythmia detection and classification circuit and the biologic therapy delivery device, the control circuit programmed to trigger the delivery of the one or more agents including the expression cassette and the regulatory signal from the biologic therapy delivery device in an amount effective to restore or prolong action potential duration(APD) and/or effective refractory period (ERP) in response to a detection of a tachyarrhythmia classified as AF. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
Specification